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ABSTRACT
The prognosis for childhood acute lymphoblastic leukemia (ALL) has improved dramatically over the past
quarter of a century. Despite improvements in the treatment of childhood ALL, relapse still occurs in
20%-30% of patients. Although many of these relapses occur in the “standard-risk” patients, approximately
10% of these patients present at diagnosis with clinical and biological features that identify them as having a
very high risk of relapse. Children (2 months to 21 years) with >1 ultra-high-risk feature (UHRF) of ALL in
first remission treated on a frontline Children’s Cancer Group (CCG) ALL study with a matched family
allogeneic donor were eligible for study entry onto CCG-1921 and an allogeneic bone marrow transplant
(AlloBMT). Each patient received fractionated total body irradiation (1200 cGy) and cyclophosphamide (120
mg/kg) conditioning therapy followed by unmobilized BM from a matched family donor. Graft-versus-host
disease (GVHD) prophylaxis consisted of methotrexate and cyclosporin. Twenty-nine patients with a median
age of 8.7 years with UHRF ALL in first complete remission (CR1) received an AlloBMT from a family
member. The incidence of grade II-IV acute GVHD was 20.7% and the incidence of chronic GVHD was 3.7%.
AlloBMT conditioning regimen was well tolerated and only 1 patient (3%) had treatment-related mortality.
Ten patients (35%) died due to progressive disease. The 5-year event-free survival (EFS) for all patients was
58.6% and patients without cytogenetic abnormalities had a 5-year EFS of 77.8%. The 5-year EFS rates for
infants and non-infants were 20.0% and 66.7% (log-rank test, P .01), respectively. Patients with Philadelphia
chromosome-positive ALL had a 5-year EFS of 66.7%. The children with UHRF of ALL may benefit from
AlloBMT in CR1, especially patients with primary induction failure and Philadelphia chromosome-positive
ALL. Randomized prospective cooperative group studies are required to establish the role of allogeneic
hematopoietic stem cell transplantation versus intensive chemotherapy in children with UHRF ALL in CR1.
© 2007 American Society for Blood and Marrow Transplantation
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The prognosis for childhood acute lymphoblastic
eukemia (ALL) has improved dramatically over the
ast quarter of a century. Currently, 2500 children
n the United States are diagnosed each year with ALL
nd almost 95% attain a clinical remission after 3- or
-drug induction chemotherapy [1-4]. Presently,
70%-83% of children with newly diagnosed ALL
reated with multiagent chemotherapy with or with-
ut clinical radiotherapy are alive and disease free at 5
ears [5-8]. In the Children’s Cancer Group (CCG)
941 study, children with ALL who developed initial
one marrow (BM) relapse within 12 months of com-
letion of primary therapy received allogeneic BM
ransplantation (AlloBMT) or prolonged intensive
hemotherapy. The overall survival and event-free sur-
ival (EFS) at 5 years for all children were 18% and 16%,
espectively. Children assigned to receive matched re-
ated AlloBMT versus chemotherapy achieved a 5-year
isease-free survival of 29% versus 20%, respectively [9].
owever, patients who relapse within the ﬁrst year of
iagnosis have a dismal outcome [10].
Despite recent advances in the diagnosis and treat-
ent of childhood ALL, there are several subgroups
f patients in ﬁrst complete remission (CR1) who have
high risk of failing current multiagent chemotherapy
egimens and who require alternative treatment strat-
gies to prevent progression and/or relapse of their
isease [11,12].
In 1992 we reviewed the outcome of newly diag-
osed children with ALL treated previously on CCG-
00 and -1800 series of ALL multiagent chemother-
py protocols. We identiﬁed several subgroups of
hildren with ultra-high-risk features (UHRFs;
able 1) at diagnosis or during induction chemother-
py that were associated with 40% 5-year EFS.
An alternative treatment strategy to intensive mul-
iagent chemotherapy for newly diagnosed children with
HRF of ALL is matched related AlloBMT. However,
ith a few exceptions, matched related AlloBMT had
able 1. Ultra-High-Risk Criteria of Childhood ALL in CR1
>1 of the following
Cytogenetics
t(9; 22) (q34, q11) or BCR-ABL molecular rearrangement
t(4;11) (q21, q23) or 11q23 molecular rearrangement
Hypodiploidy (<44 chromosomes)
Age >10 y and WBC count >200,000/mm3
Induction failure (day 28 M2 or M3 BM)
Infant ALL (2-12 mo) with >1 of the following
CD10 (CALLA) ALL phenotype
WBC count >100,000/mm3 at diagnosis
Day 14 M2 or M3 BM
LL indicates acute lymphoblastic leukemia; CR1, ﬁrst complete
remission; WBC, white blood cell; M2/M3, marrow status (5-
25% blasts)/marrow status (25% blasts); BM, bone marrow;bCALLA, common acute lymphoblastic leukemia antigen.reviously been restricted to children who relapsed dur-
ng or after primary intensive multiagent chemotherapy
nd not after CR1. We therefore conducted a clinical
esearch study from 1993 to 1996 to investigate the
oxicity and efﬁcacy of matched related AlloBMT in
ewly diagnosed children with UHRF of ALL at di-
gnosis and/or during initial induction chemotherapy
CCG-1921).
ETHODS
ligibility
Children (2 months to 21 years) with 1 UHRF
f ALL (Table 1) in CR1 treated on a frontline CCG
LL study and with a matched family allogeneic do-
or were eligible for study entry onto CCG-1921 and
n AlloBMT. However, patients with an M3 marrow
fter induction and consolidation were ineligible and
atients with L3 or Burkitt leukemia were also ineli-
ible. Organ function requirements before AlloBMT
ncluded serum creatinine 1.5 times normal or glo-
erular ﬁltration rate 40 mL/(min · m2) or creati-
ine clearance 70 mL/(min · 1.23 m2) for renal
unction; bilirubin 1.5 times normal and aspartate/
lanine aminotransferase 2.5 times normal for liver
unction; shortening fraction 27% or ejection frac-
ion47% for cardiac function; and forced expiratory
olume/forced vital capacity 60% normal or pulse
ximetry 94% in room air for pulmonary function.
LA Donor and Recipient HLA Matching Criteria
Patients with an HLA-A, -B, -DR genotypically or
henotypically identical parent or sibling or 1 antigen
ismatch (ie, 1 haplotype identical and 1 single locus
ismatch on nonidentical haplotype, 6/6 or 5/6) were
ligible for study. A, B, and DR typing was performed
t each local institution by serologic methods.
rior Therapy (Induction and Consolidation Therapy)
Each patient must have completed induction ther-
py and 4 weeks of consolidation chemotherapy
with or without prophylactic cranial radiation ther-
py). AlloBMT must have been performed within 4
onths of original diagnosis of ALL and start of
hemotherapy and before the beginning of delayed
nduction/intensiﬁcation therapy.
onsent
All patients and/or the patient’s legal authorized
uardian gave written consent to participate in this
rial. Only those institutions approved by CCG to
erform AlloBMT were allowed to participate in this
rial. Each institution participating in this trial had this
rotocol approved by their local institutional review
oard in compliance with the Declaration of Helsinki.
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P. Satwani et al.220reparative Therapy (Conditioning)
Each patient received fractionated total body irra-
iation (TBI; 1200 cGy), with a midplane dose rate of
-10 cGy/min, and cyclophosphamide (120 mg/kg)
onditioning therapy. The schedule was: day6, 200-
Gy TBI twice daily; day 5, 200-cGy TBI twice
aily; day 4, 200-cGy TBI twice daily; day 3,
yclophosphamide 60 mg/kg intravenously over 1
our; day 2, cyclophosphamide 60 mg/kg intrave-
ously over 1 hour; and day 0, unmobilized BM from
atched family donor. Mesna and/or bladder irriga-
ion for bladder prophylaxis was at the discretion of
he individual institution.
raft-versus-Host Disease Prophylaxis
Each patient received methotrexate (MTX) 15 mg/m2
ntravenously on day 1 and MTX intravenously 10
g/m2 on days 3, 6, and 11. Cyclosporin was
egun on day 1 at a dose of 1.5 mg/kg intravenously
very 12 hours and switched to oral cyclosporin when
olerated at a starting dose of 6.25 mg/kg orally every
2 hours. Cyclosporin was continued until day 50
nd then recommended to be tapered at 5%/week if
rade II acute graft-versus-host disease (GVHD)
ccurred.
upportive Care
Protective isolation procedures were recom-
ended and implemented at the discretion of each
MT institution. Granulocyte-macrophage colony-
timulating factor (500 g/m2) was started on day 0 at
hours after BM infusion and given intravenously
ver 2 hours daily until day21 and was discontinued
hen the absolute neutrophil count (ANC) was
1500/mm3  3 days. Intravenous immune Globulin
500 mg/kg) was started on day 1 and continued
eekly until discharge from the hospital and then
ontinued monthly until day180. Acyclovir prophy-
axis (250-500 mg/m2 intravenously) every 8 hours was
tarted on day 6 and continued until day 30 or
ischarge from the hospital, whichever occurred
ooner. Ganciclovir prophylaxis was administered to
ll cytomegalovirus (CMV) serologically positive re-
ipients and to CMV-negative recipients who began
o excrete CMV when their ANC was750/mm3 2
ays at a dose of 5 mg/kg every 12 hours  5 days and
hen 5 mg/kg daily (6 days/week) until day 100 or
ischarge, whichever occurred sooner. Recipients who
eceived a CMV-negative BMT also received CMV-
egative blood products. Trimethoprim-sulfamethox-
zole (5 mg/kg daily divided into 2 doses) was adminis-
ered to all patients until day 1 and then reinitiated 3
imes/week when the ANC recovered to500/mm3 2
ays after BMT. wone Marrow Donors
Family donors were screened, consented, and had
BM harvest performed according to institutional
rocedures. The donors were unmobilized and 3 
08 nucleated cells were harvested and collected.
here were no speciﬁc requirements for minimum
umber of CD34 cells.
entral Nervous System Intrathecal Prophylaxis
fter BMT
Patients who did not receive prophylactic cranial
rradiation during initial consolidation or during the
reparative therapy were administered intrathecal
TX starting on day 100 every 3 months for a total
f 6 doses at age-appropriate doses (1 year, MTX 3
g; 1-2 years, MTX 6 mg; 2-3 years, MTX 8 mg;
-12 years, MTX 10 mg; 12 years, MTX 12 mg).
erformance Status
Lansky score was performed for children and ad-
lescents 16 years of age and Karnofsky score for
dolescents 16 years of age every 1-3 months after
ransplantation [13,14].
tudy Design and Statistical Methods
The CCG-1921 study was originally designed and
onducted so that, in addition to the patients who were
nrolled on the clinical trial, data were collected on
atients who had the corresponding high-risk features
nd were (1) not eligible for CCG-1921 because no
uitable sibling donor was available or (2) eligible for
CG-1921 but were not enrolled. Data on these latter 2
ategories of patients were obtained from the roster of
atients enrolled on all open CCG studies for children
ith ALL during the period that this study was con-
ucted. The ﬁrst of these 2 groups was intended to
erve as a “control” group for comparing outcome of
atients receiving chemotherapy with those receiving
ransplant in CCG-1921. Eligibility criteria required
hat all patients entering CCG-1921 had to be in CR1
nd had completed induction and consolidation ther-
py on a frontline CCG ALL trial before transfer and
ntry into this study. This same criterion was applied
o the control group. Data on the second group being
reated on their original frontline CCG ALL trial was
ntended for use in identifying outcome of eligible
atients who did not get enrolled on the study and for
se in “intent-to-transplant” analyses (where they
ould be combined with those enrolled on the CCG-
921 study for comparison with the chemotherapy
ontrol group).
In the initial planning of this study, sample size
nd power calculations were based on a proportional
azards rate assumption for the treatment regimens
ith no events assumed to occur after 4 years of
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AlloBMT in Children with Ultra-high-risk ALL 221ollow-up and a baseline EFS plateau of 30% at that
ime. The study was sized so that a change in EFS
utcome from a 30% to a 46% ﬁnal plateau would
ave in excess of 80% power when comparing the
ransplant group with the control group (81.5%
ower for 2-sided log-rank test). These planning as-
umptions resulted in a requirement for approximately
00 patients entered in CCG-1921 and assumed about
00 in the chemotherapy control group. During the
onduct of the study, all frontline CCG ALL trials
losed because the accrual goals had been completed.
t became impossible to follow the control patients
ot going on to transplantation and the number of
ligible patients for AlloBMT began to decrease
ecause of no open CCG ALL frontline chemother-
py trials. These problems eventually led to the
losure of the study without achieving the planned
ccrual goals. The ﬁnal accrual to CCG-1921 in-
luded 29 patients.
The primary endpoint used for life table compar-
sons of treatment regimen outcome and prognostic
actor effects is EFS from study entry (or from an
ppropriate baseline time for chemotherapy control
atients or patients who were eligible for study entry
ut not enrolled). This endpoint is deﬁned as the time
o the ﬁrst occurrence of any 1 of the following events:
elapse after initial remission at any site, death in
emission, or second malignant neoplasm. Selected
omparisons of survival outcome are provided. Life
able estimates used the Kaplan-Meier method [15],
nd standard deviations of the Kaplan-Meier estimate
ere calculated with the Peto variance formula [16].
or life table description and analysis of outcome in
he chemotherapy control group and eligible but no-
ransplantation group, only those patients were as-
essed who reached 122 days from diagnosis still in
emission because this was the protocol-intended
aximum time from diagnosis to transplantation in
he CCG-1921 patients.
Life table outcome for the CCG-1921 patients
as calculated from time of transplantation. Because
f the possibility that nonproportional hazards might
ccur when comparing transplantation outcome with
hemotherapy, the study protocol also emphasized the
mportance of directly comparing outcome at a rele-
ant length of late follow-up where the EFS estimates
ould be close to their plateau values. Life table com-
arisons use the log-rank statistic for assessment
cross the entire time scale, and a comparison of the
aplan-Meier 4-year estimates for late outcome. Rel-
tive hazard rates are estimated by the log-rank ob-
erved/expected method. Life table methods are also
sed to provide estimates for the ﬁrst occurrence of
cute GVHD and the time to myeloid and platelet
ngraftment for the CCG-1921 patients. (ESULTS
atient Demographics and Disease Characteristics
This prospective study was conducted at various
CG-afﬁliated centers over 4 years (1993-1996).
wenty-nine patients with UHRF ALL in CR1 re-
eived AlloBMT from a family member (Table 2).
he median age was 8.7 years (range, 0.5-17.5 years)
nd gender distribution was 20 males and 9 females.
wenty patients had cytogenetic abnormalities: 9 with
(9;22), 3 with t(4;11), 5 with hypodiploidy, and 3 with
ombined ultra-high-risk cytogenetic abnormalities.
here were 5 patients with ultra-high-risk cytogenet-
cs and additional UHRF ALL. Five patients were
nfants (6-12 months) and 7 patients had induction
ailure and/or10 years of age with a white blood cell
ount 200,000/mm3.
llogeneic Stem Cell Donors
All 29 patients received transplants from matched
ibling donors (MSDs), 28 patients received 6/6 and 1
atient received 5/6 HLA matched AlloBMT. Median
umber of days from diagnosis to AlloBMT was 101
ays.
ematologic Reconstitution after AlloBMT
Median time to achieve an ANC 500/mm3 was
1 days (range, 12-49 days) and median time to
chieve a platelet count 20 000/mm3 untransfused
or 3 days was 24 days (range, 3-107 days).
VHD (Acute and Chronic)
MTX dosing was held in 7 of 29 patients. Four
atients missed the fourth dose, 1 patient missed the
hird dose, 1 missed 2 doses, and 1 missed 3 doses.
ncidences of grade II-IV and III-IV acute GVHD
ere 20.7% and 6.9%, respectively. Organ involve-
ent included grade I skin (n 5), grade II skin (n 1),
rade III skin (n  5), grade I liver (n  1), grade III
iver (n  1), grade I gut (n  1), and grade II gut (n
) acute GVHD. Incidence of chronic GVHD was
.7%. Treatment for GVHD was at the discretion of
he institutional principal investigator.
rade III and IV Toxicities
No unexpected non-hematologic toxicities were
bserved. There was one death due to adult respira-
ory distress syndrome (3%). The most common tox-
city was mucositis (62%). Other toxicities included
ypertension (28%), non-life threatening infections
48%), life threatening infections (20%), transaminitis
20%), veno-occlusive disease of the liver (6%) and
nterstitial pneumonitis secondary to CMV (7%). Life
hreatening infections included four cases of sepsis
Staphylococcus coagulase negative, Streptococcus viridans
Table 2. Patient Characteristics and Outcome Features of Childhood ALL in CR1 with Ultra-high-risk Features
Patient
ID
Age(y)/
Sex Eligibility Criteria Prior Therapy
Time of
Diagnosis to
AlloBMT(d)
Myeloid
Recovery*
(d)
Platelet
Recovery†
(d)
aGVHD
(Grade)
Follow-up
after
AlloBMT (y)
Status
(Cause of
Death)
Performance Score
of Surviving
Patients at Last
Follow-up KPS/LS
A-1 13.9/F t(4;11)(q21;q23) CCG-1882§ cycles 1 and 2 93 27 25 0 0.78‡ Dead (PD) Dead
A-2 9.0/M IF CCG-1922 cycle 1 110 19 25 0 4.2 Alive 100
A-3 12.1/F t(9;22)(q34;q11.2) NA-LI 103 26 33 II 0.98‡ Dead (PD) Dead
A-4 11.7/M t(9;22)(q34;q11.2) CCG-1882 cycles 1 and 2 97 22 24 0 3.5 Alive 100
A-5 8.75/F CA NA-LI 104 1 17 0 1.25‡ Dead (PD) Dead
BB-1 1.0/M Infant and CALLA NEG, t(4;11)(q21;q23), IF NA-LI 125 21 14 0 3.8 Alive 100
BB-2 3.8/M IF NA-LI 99 20 24 0 2.8 Alive 100
BB-3 0.5/M Infant and CALLA NEG, t(4;11)(q21;q23) NA-LI 71 12 15 0 1.7 Alive 100
C-1 6.4/F IF CCG-1922 cycles 1 and 2 122 19 14 0 4.0 Alive 100
EE-1 10.7/F t(9;22)(q34;q11.2) CCG-1882 cycles 1 and 2 123 22 23 III 4.0 Alive 100
GG-1 16.1/M Hypodiploid 27XY CCG-1882 cycles 1 and 2 176 21 16 0 4.4 Alive 100
GG-2 17.7/M Hypodiploid 26X, Y, IF NA-LI 91 18 19 II 2.31‡ Dead (PD) Dead
H-1 14.3/M IF NA-LI 90 29 NA I 0.68 Alive 100
JJ-1 0.8/M Infant and CALLA NEG, t(4;11)(q21;q23) NA-LI 92 12 14 I 0.54‡ Dead (PD) Dead
K-1 3.5/M t(9;22)(q34;q11.2) CCG-1922 cycles 1 and 2 182 25 19 0 4.2 Alive 100
MM-1 17.2/M IF CCG-1882 cycles 1-4 222 25 24 I 4.6 Alive 100
MM-2 12.2/F t(9;22)(q34;q11.2) CCG-1882 cycles 1-3 128 49 107 I 4.1 Alive NA
N-1 2.4/M t(9;22)(q34;q11.2), IF CCG-1922 cycles 1 and 2 102 20 19 I 2.5‡ Dead (PD) Dead
N-2 17.6/M >10 y and WBC count >200 000/mm3 CCG-1882 cycles 1-3 137 24 30 III 4.0 Alive 100
N-3 6.6/F CA CCG-1882 cycles 1-3 91 21 14 0 3.5 Alive 100
NN-1 12.1/M t(9;22)(q34;q11.2) CCG-1882 cycles 1 and 2 104 16 17 I 4.7 Alive 100
NN-2 15.5/M >10 y and WBC count >200 000/mm3 CCG-1882 cycles 1 and 2 97 17 24 II 3.8 Alive 100
NN-3 6.8/M Hypodiploid 26X, Y NA-LI 97 16 19 0 0.61‡ Dead (PD) Dead
OO-1 2.1/M Hypodiploid 26X, Y CCG-1882 cycles 1 and 2 88 18 20 I 0.80‡ Dead (PD) Dead
P-1 0.9/M Infant and CALLA NEG CCG-1883¶ cycles 1 and 2 79 14 26 0 0.7‡ Dead (PD) Dead
QQ-1 5.0/M Hypodiploid <44 chromosomes, IF NA-LI 102 34 3 0 3.2 Alive 100
U-1 0.5/F <6 mo at diagnosis CCG-1883 cycles 1 and 2 101 17 21 0 3.3‡ Dead (PD) Dead
X-1 14.1/F CA NA-LI 110 26 32 0 2.1 Alive 100
Z-2 13.2/M t(9;22)(q34;q11.2) CCG-1901# cycles 1 and 2 112 28 3 II 0.1 Dead (toxicity) Dead
ALL indicates acute lymphoblastic leukemia; CR1, ﬁrst complete remission; AlloBMT, allogeneic bone marrow transplantation; aGVHD, acute graft-versus-host disease; KPS, Karnofsky performance
score; LS, Lansky score; F, female; M, male; CCG, Children’s Cancer Group; PD, progressive disease; IF, induction failure; CA, cytogenetic abnormality; CALLA, common acute lymphoblastic
leukemia antigen; NEG, negative; NA-LI, not available/treated as per local institutional protocol; WBC, white blood cell.
*Myeloid recovery, absolute neutrophil count 500/mm3.
†Platelet recovery, 20 000/mm3.
‡Time to relapse.
§CCG-1882 therapy: cycle 1 consists of vincristine, prednisone, daunomycin, cytarabine, l-asparaginase, and methotrexate; cycle 2 consists of cyclophosphamide, 6-mercaptopurine, cytarabine,
methotrexate, and radiation therapy; cycle 3 consists of 6-mercaptopurine and methotrexate; cycle 4 consists of vincristine, Adriamycin, dexamethasone, l-asparaginase, cyclophosphamide,
6-thioguanine, cytarabine, and methotrexate.
CCG-1922 therapy: cycle 1 consists of vincristine, dexamethasone, l-asparaginase, and intrathecal methotrexate; cycle 2 consists of vincristine, prednisone, 6-mercaptopurine, methotrexate, and
intrathecal methotrexate.
¶CCG-1883 therapy: cycle 1 consists of prednisone, vincristine, daunomycin, l-asparaginase, intrathecal methotrexate, and cytarabine; cycle 2 consists of vincristine, cyclophosphamide, methotrexate,
intrathecal methotrexate, and cytarabine.
#CCG-1901 therapy: cycle 1 consists of daunomycin, cyclophosphamide, vincristine, prednisone, l-asparaginase, cytarabine, and methotrexate; cycle 2 consists of prednisone, l-asparaginase, cytarabine,
and vincristine.
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AlloBMT in Children with Ultra-high-risk ALL 223nd aspergillosis, Staphylococcus aureus, multiple organ-
sm) and two patients developed CMV pneumonitis.
verall Survival
The AlloBMT conditioning regimen was well tol-
rated and only 1 patient (3%) had treatment-related
ortality. Ten patients (35%) died due to disease
elapse. The 5-year EFS for all patients was 58.6%
n  29; Figure 1). Patients without cytogenetic ab-
ormalities had a 5-year EFS of 77.8% (n  9). The
-year EFS rates for infants and non-infants were
0.0% and 66.7% (log-rank test, P  .01), respec-
ively. Patients with Philadelphia chromosome-posi-
ive (Ph) ALL (n  9) had a 5-year EFS of 66.7%
Figure 2). Five of 7 patients with induction failure
urvived and the 5-year EFS was 71%.
ISCUSSION
Despite improvements in the treatment of child-
ood ALL, relapse still occurs in 20%-30% of pa-
ients. Although many of these relapses occur in the
tandard-risk patients, approximately 10% of these
atients present at diagnosis with clinical and biolog-
cal features that identify them as having a very high
isk of relapse. This probability of relapse can increase
p to 50% for some patients presenting with UHRF
2,3,17,18]. This study demonstrated a 5-year EFS in
9% of children with UHRF ALL who received an
lloBMT in CR1. These results are comparable to
hose of other published studies in children with
HRF ALL in CR treated with AlloBMT or alloge-
eic stem cell transplantation (AlloSCT; Table 3).
urrently, the Children’s Oncology Group is con-
ucting a study (AALL0031) for feasibility of an in-
ensiﬁed chemotherapeutic regimen incorporating
ovel agents for treatment of children and adolescents
igure 1. Probability of 5-year event-free survival (EFS) by Kaplan-
eier estimates in children with ultra-high-risk features of acute
ymphoblastic leukemia in ﬁrst complete remission treated with
llogeneic bone marrow transplantation in the Children’s Cancer
roup 1921 study.ith very-high-risk ALL. In this study, patients with dLA matched related donors will receive short inten-
ive consolidation followed by AlloSCT.
Conventional chemotherapy can induce remis-
ions in 50%-70% of patients with Ph ALL. How-
ver, maintenance chemotherapy fails to maintain du-
able CRs and is associated with an overall survival of
nly 6%-20% [19-21]. Similarly, the approach of aug-
ented postinduction chemotherapy, including high-
ose chemotherapy with or without autologous stem
ell rescue, has failed to improve the outcome for
atients who have Ph ALL [20-23]. Myeloablative
hemotherapy followed by hematopoietic stem cell
escue from an allogeneic donor in CR1 has been
hown to cure 20%-75% of patients [24-34]. Schrappe
t al [35], in a study of 61 patients with Ph ALL,
emonstrated a signiﬁcant survival advantage of
atched related donor AlloBMT when compared
ith chemotherapy (4-year EFS, 83% versus 28%,
espectively). In another study of childhood Ph ALL,
oy et al [36] demonstrated that the 3-year EFS for
atients who underwent transplantation (MSD plus
atched related donor) in CR1 was 60% and that for
atients who did not undergo BMT in CR1 was 36%.
n our present study the 5-year EFS for children with
h ALL who received AlloBMT in CR1 was 66.7%.
The persistence of leukemia at the end of 1 month
f induction therapy is a strong independent predictor
f poor outcome in children with ALL. Most children
ho are refractory to initial induction therapy even-
ually achieve a CR. However, these children are at
ery high risk of early relapse, particularly if their
ubsequent therapy consists of conventional chemo-
herapy [37]. Silverman et al [37] reported a 16%
-year EFS for children with persistent leukemia after
month of induction chemotherapy. In the CCG-
950/60s series, the 5-year estimated survival in 26
hildren with ALL who did not attain remission after
nduction chemotherapy was 30.1% (Sather et al, per-
onal communication). AlloBMT might be more ef-
igure 2. Probability of 5-year event-free survival (EFS) by Kaplan-
eier estimates in children with Philadelphia chromosome-positive
(9;22) acute lymphoblastic leukemia in ﬁrst complete remission
reated with allogeneic bone marrow transplantation in the Chil-
ren’s Cancer Group 1921 study.
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P. Satwani et al.224ective than chemotherapy as postremission therapy
or patients who are refractory to initial induction
herapy. In 1 study with short follow-up (2 years), 6
f 8 children with ALL (75%) who were initially
efractory to induction therapy after diagnosis re-
ained in CR after receiving a sibling-matched BMT
n ﬁrst remission [38] . In another series with a median
ollow-up of 5.5 years, 10 of 18 patients (56%), in-
luding adults and children with induction failure
LL, remained in CR after a sibling-matched BMT in
R1 [39]. Others have reported lower EFS rates after
ibling-matched BMT for patients with ALL refrac-
ory to initial induction therapy, but some of these
tudies have included patients who never achieved CR
40]. In the present study, the 5-year EFS for children
ith ALL and induction failure was 71%.
ALL is rare in infants, who have a worse prognosis
ompared with older children. The 5-year EFS of infant
atients with ALL treated with conventional chemother-
py and after intensive multiagent chemotherapy ranges
etween 25% and 45% [41-44]. In the recently pub-
ished CCG-1953 infant ALL study, the 5-year EFS
or 115 infants was 41.7% [45]. To date, no large
rospective studies have been conducted regarding the
fﬁcacy of AlloBMT in the treatment of infants with
LL. Pirich et al [46] reported 7 infants with ALL
ho received an AlloBMT. Four of these 7 patients
urvived from 1.3 to 5.4 years at the time of the report.
ui et al [47,48] reported the outcome of infants with
(4;11) ALL treated by cooperative groups or single
nstitutions. Infants treated with chemotherapy (n 
03) had a survival rate of 33%, and among the 28
ho received any type of BMT the survival rate was
5%. Sanders et al [49] reported a 76% EFS for
nfants with ALL after AlloSCT in CR1 compared
able 3. Results of Various Studies in Children with UHRF of ALL in
Study
Patients,
n UHRF of ALL
CG-1921 29 t(9; 22) t(4;11), hypodiploidy, age >1
and WBC count >200  109/L,
induction failure, infant ALL
heeler et al
[53]
101 t(9; 22), hypodiploidy, T cell ALL, ag
>10 y and WBC count >200  10
induction failure, infant ALL
hessells et al
[54]
34 WBC count >100  109/L, T cell AL
aarinen et al
[55]
22 WBC count >50  109/L, T cell ALL
CNS-ALL, t(4;11), induction failur
Infant ALL
alduzzi et al
[56]
55 Poor response to prednisone, induct
failure, t(9; 22) t(4;11), T cell ALL
and WBC count >100  109/L
HRF of ALL indicates ultra-high-risk features of acute lymphoblas
MUD, matched unrelated donor; MMSD, mismatched sibling
cyclophosphamide; HD-ARA-C, high-dose cytosine arabinosi
survival; CNS, central nervous system; WBC, white blood cell.ith 45% after AlloSCT for CR2/CR3 versus 8% pfter AlloSCT in active relapse (P  .001). Recently,
acobsohn et al [50] reported a 75% 3-year overall
urvival for 16 infants in CR1 after MSD (n  8) and
mbilical cord blood transplantation (n  8). In our
CG-1921 study, only 2 of 5 infants (40%) with ALL
n CR1 after AlloBMT survived.
Transplant-related mortality is a major concern
or patients receiving AlloBMT. Transplant-related
ortality can be seen in 15%-23% in patients after
SD AlloBMT with different conditioning regimens
51]. However, in our CCG-1921 study, transplant-
elated mortality was only 3%. This difference is
robably due to the fact that patients in CR1 had
eceived less prior chemotherapy and had better per-
ormance status compared with patients in CR2 and
R3. However, in the CCG-1921 study, disease pro-
ression resulted in 10 deaths (35%). In a larger series
f patients receiving MSD AlloBMT after condition-
ng with cyclophosphamide/TBI for ALL (CR1 
R2, CR3), the 3-year probability of leukemia-free
urvival (LFS) was 50% [51]. In the CCG-1921 study,
he 5-year EFS in children with UHRF of ALL who
eceived AlloBMT in CR1 was 58.6%.
The effect of conditioning regimens on various
ransplantation outcomes in children and adults with
LL was recently analyzed by the International Bone
arrow Transplant Registry. [52] In patients with high-
isk ALL in CR1, comparisons of various pretransplan-
ation conditioning regimens (cyclophosphamide/TBI
13 Gy versus cyclophosphamide/TBI13 Gy versus
toposide/TBI 13 Gy versus etoposide/TBI 13 Gy)
id not demonstrate any signiﬁcant difference in
ransplant-related mortality, relapse rate, LFS, and
verall survival. However, in CR2, standard cyclo-
Donor
Conditioning
Regimen
TRM,
%
Relapse
Rate, %
5-y
EFS, %
MSD TBI/CY 3 35 56.8
MSD, MUD TBI/CY 18 31 45.3
MSD TBI/CY 17 11 58
MSD, MMSD,
MPD
TBI/CY, HD-ARA-
C/TBI, BU/CY
13 9 73
MSD TBI/etoposide, BU/
CY/etoposide
9 34 56
emia; CR1, ﬁrst complete remission; MSD, matched sibling donor;
MPD, matched paternal donor; TBI, total body irradiation; CY,
, busulfan; TRM, transplant-related mortality; EFS, event freeCR1
0 y
e
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AlloBMT in Children with Ultra-high-risk ALL 225cantly poorer outcomes (relapse, overall survival, and
FS) [52].
This was the ﬁrst and largest cooperative study
onducted by CCG for patients with UHRF ALL in
R1 who underwent AlloBMT. However, clinical tri-
ls in pediatrics attempting to compare BMT against
onventional chemotherapy in a rigorous manner are
ifﬁcult to carry out successfully. Part of this problem
elates to the issue of appropriate enrollment of the
arget population in a trial because some institutions
r physicians may be unwilling to enroll all their
ligible patients. Another problem is “crossover” of
atients who are supposed to receive 1 treatment but
ctually receive another treatment. Even in the face of
uch difﬁculties, it may be possible to conduct such trials.
ne way should be to strive for eligibility criteria that are
ot overly controversial such that participating investi-
ators would be comfortable entering the deﬁned patient
roups. It is also important to have an approach for
dentifying any study nonentrants from participating in-
titutions and have a system that permits one to track
heir treatment and eventual outcome. This will permit
xamination of the degree of selective patient enrollment
nd facilitate analysis of the study population together
ith the remaining patients in the target population.
In summary, children with UHRF of ALL may
eneﬁt from AlloBMT in CR1, especially patients
ith primary induction failure and Ph ALL. How-
ver, the results of this study should be interpreted
autiously due to the small number of patients ac-
rued. Randomized prospective cooperative group
tudies are required to establish the role of AlloSCT
ersus intensive chemotherapy in children with
HRF ALL in CR1.
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